SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

LYL273

LYEL·Lyell Immunopharma, Inc
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1/2
Time to market
Likely several years away. LYL273 is in Phase 1/2 dose-finding. The End-of-Phase 1 FDA meeting is expected in 2027, after which a potential pivotal Phase 2 trial would need to enroll and read out before any BLA submission, likely no earlier than 2028-2029 if all goes well.
Why 4/10
LYL273's next catalysts are additional Phase 1 clinical data and an End-of-Phase 1 FDA meeting, both now expected in 2027 (no specific date given). With no hard dated binary catalyst within the next ~12 months, and LYL273 being Lyell's secondary program behind ronde-cel (the primary value driver), the impact score is limited to 4.
Actionable Insight NEUTRAL

The next catalysts for LYL273 are additional Phase 1 clinical data and an End-of-Phase 1 meeting with the FDA, both now expected in 2027 (pushed from H2 2026). Positive data and regulatory alignment could open a path to a pivotal Phase 2 trial; a safety or efficacy miss would significantly damage the program's prospects. However, Lyell's primary near-term value driver is ronde-cel (BLA submission H2 2027), so LYL273 updates are secondary for the stock.

Price Chart

Loading chart...

Executive Summary

LYL273 (formerly GCC19CART) is a next-generation CAR T-cell therapy targeting guanylyl cyclase C (GCC) for metastatic colorectal cancer (mCRC), acquired by Lyell Immunopharma from Innovative Cellular Therapeutics in November 2025. Early Phase 1 data showed a 67% overall response rate at the highest dose level (6 patients) and a 50% ORR across dose levels 1 and 2. A June 2026 safety update demonstrated improved tolerability with a GI prophylaxis regimen. However, the program's timeline has slipped: the End-of-Phase 1 FDA meeting and additional clinical data were pushed from H2 2026 to 2027 (announced September 2026). LYL273 is Lyell's second clinical asset behind lead candidate ronde-cel (for large B-cell lymphoma), which is the company's primary near-term value driver with a BLA submission planned for H2 2027.

How It Works

LYL273 is a CAR T-cell therapy, a personalized cancer treatment made from a patient's own immune cells. The patient's T cells (a type of white blood cell) are collected, genetically modified in a lab to recognize a protein called guanylyl cyclase C (GCC) found on colorectal cancer cells, and then infused back into the patient. LYL273 includes two additional engineering features: it also expresses a CD19-targeting CAR to help the cells expand better in the body, and it has controlled cytokine release to reduce side effects. The goal is to help the modified T cells find, infiltrate, and kill solid tumors.

Trial Status

The CARABiNER trial (NCT05319314) is an ongoing Phase 1/2 open-label, multicenter study in relapsed/refractory metastatic colorectal cancer. As of May 5, 2026, 19 patients had been enrolled across Dose Levels 1 and 2. The Phase 1 dose-escalation portion is determining the recommended Phase 2 dose; the Phase 2 portion will expand enrollment in a single-arm cohort. Manufacturing transfer to Lyell's Bothell, WA facility was completed in September 2026.

The Two-Sided Case

▲ Bull Case5
Promising early efficacy: LYL273 showed a 67% overall response rate and 83% disease control rate at the highest dose level in heavily pre-treated, refractory metastatic colorectal cancer patients, a population with very limited options.
Improved safety with prophylaxis: The June 2026 update showed a GI prophylaxis regimen reduced Grade >=2 diarrhea/colitis from 55% to 10%, with no Grade 3+ CRS or ICANS, suggesting a manageable safety profile.
FDA Fast Track designation: LYL273 received Fast Track from the FDA for mCRC, which can enable more frequent interactions and rolling review.
Manufacturing milestone completed: The technology transfer to Lyell's own LyFE facility in Bothell, WA was successfully completed (Sept 2026), giving the company internal manufacturing control.
Analyst support: 12 of 14 analysts rate Lyell Buy or Strong Buy, with a mean price target of $37.88 (152.5% upside from the Nov 5 close of $15). Needham reiterated Buy on Nov 3, 2026.
▼ Bear Case5
Timeline slippage: The End-of-Phase 1 FDA meeting was pushed from H2 2026 to 2027 (announced Sept 10, 2026), signaling slower-than-expected enrollment or dose optimization.
Very small efficacy dataset: The 67% ORR cited at acquisition came from just 6 patients at the highest dose level; the broader 50% ORR across Dose Levels 1 and 2 (data cutoff Oct 28, 2025) was based on 12 patients total.
Solid tumor CAR T is unproven: No CAR T-cell therapy has been approved for a solid tumor like colorectal cancer. LYL273 faces inherent biological challenges in the tumor microenvironment despite its engineering enhancements.
Dilution risk: Lyell completed an $80M private placement at $10.77/share on Nov 4, 2026, adding 7.4M shares. The stock closed at $15 on Nov 5, 2026, well below its 52-week high of $45.
Secondary program: LYL273 is Lyell's second clinical asset behind ronde-cel (LBCL). If ronde-cel stumbles, the company's financial position could weaken before LYL273 reaches later-stage trials.

Upcoming Catalysts

  • Additional Phase 1 clinical data including efficacy outcomes (expected 2027)
  • End-of-Phase 1 meeting with the FDA (expected 2027)
  • Potential expansion into Phase 2 pivotal single-arm trial pending regulatory alignment

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Lyell Immunopharma, Inc Press Release LYEL ·Originating report

Sources · 7

Hover a chip for the title
1 ir.lyell.com2 biospace.com3 ir.lyell.com4 biospace.com5 packgene.com6 clinicaltrialvanguard.com7 marketbeat.com